Clinical Trials Logo

T-cell Non-Hodgkin Lymphoma clinical trials

View clinical trials related to T-cell Non-Hodgkin Lymphoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05377827 Recruiting - Clinical trials for Acute Myeloid Leukemia

Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies

Start date: October 10, 2023
Phase: Phase 1
Study type: Interventional

Effective treatment options for relapsed/refractory acute myeloid leukemia (AML) and T-cell non-Hodgkin lymphoma (T-NHL) represent a significant unmet medical need. CAR T therapy has offered durable remissions and potential cures in some forms of hematologic malignancy, including B-cell acute lymphoblastic leukemia. In AML, however, CAR T approaches have been limited by the lack of suitable antigens, as most myeloid markers are shared with normal hematopoietic stem cells and targeting of these antigens by CAR T therapy leads to undesirable hematologic toxicity. Similarly, T-NHL has not yet benefited from CAR T therapy due to a lack of suitable markers. One potential therapeutic target is CD7, which is expressed normally on mature T-cells and NK-cells but is also aberrantly expressed on ~30% of acute myeloid leukemias. CAR T therapy for patients with CD7+ AML and T-NHL will potentially offer a new therapeutic option which has a chance of offering durable benefit. WU-CART-007 is a CD7-directed, genetically modified, allogeneic, fratricide-resistant chimeric antigen receptor (CAR) T-cell product for the treatment of CD7+ hematologic malignancies. These cells have two key changes from conventional, autologous CAR T-cells. First, because CD7 is present on normal T-cells including conventional CAR T products, CD7 is deleted from WU CART-007. This allows for targeting of CD7 without the risk of fratricide (killing of WU-CART-007 cells by other WU-CART-007 cells). Second, the T cell receptor alpha constant (TRAC) is also deleted. This makes WU CART 007 cells incapable of recognizing antigens other than CD7 and allows for the use of an allogeneic product without causing Graft-versus-Host-Disease (GvHD).

NCT ID: NCT05127135 Recruiting - Clinical trials for T-cell Non-Hodgkin Lymphoma

Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies

Start date: January 22, 2020
Phase: Phase 1
Study type: Interventional

This is a single dose escalation study to evaluate the safety and clinical activity of ThisCART7(Allogeneic CAR-T targeting CD7) in patients with refractory or relapsed CD7 positive T cell malignancies.

NCT ID: NCT04934774 Recruiting - Clinical trials for T-cell Acute Lymphoblastic Leukemia

Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances

Start date: December 1, 2020
Phase: Phase 1
Study type: Interventional

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of non-gene edited anti-CD7 CAR (also called anti-CD7 CAR) T cells in patients with relapsed and/or refractory T cell lymphoma or leukemia

NCT ID: NCT04823091 Recruiting - Clinical trials for T Cell Non-Hodgkin Lymphoma

Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies

Start date: April 15, 2021
Phase: Phase 1
Study type: Interventional

This is a single-center, open-label, single-arm study to evaluate the primary safety and efficacy of anti-CD7 chimeric antigen receptor(CAR)-modified T cells(CAR7-Ts) in patients with relapsed or refractory T lymphoid malignancies.

NCT ID: NCT04594135 Recruiting - Clinical trials for T-cell Acute Lymphoblastic Leukemia

Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies

CD5CAR-T
Start date: December 1, 2020
Phase: Phase 1
Study type: Interventional

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of anti-CD5 CART cells in patients with relapsed and/or refractory T cell lymphoma or leukemia.

NCT ID: NCT03590574 Recruiting - Clinical trials for Anaplastic Large Cell Lymphoma

Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma

Start date: August 30, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to test the safety and efficacy of AUTO4 a CAR T cell treatment targeting TRBC1 in patients with relapsed or refractory TRBC1 positive selected T-Non-Hodgkin Lymphoma.

NCT ID: NCT02859402 Recruiting - Clinical trials for T-cell Non-Hodgkin Lymphoma

Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas

RRTCLAlloSCT
Start date: December 2016
Phase: Phase 2
Study type: Interventional

Relapsed and refractory T-cell lymphomas have been reported to have dismal outcomes. The role of allogeneic stem cell transplantation have been demonstrated in these patients. This clinical trial is studying the efficacy and safety of busulfan plus fludarabine as conditioning therapy followed by allogeneic stem cell transplantation (Allo-SCT) in T- and NK/T-cell lymphoma patients who have relapsed or are refractory to previous chemotherapies including autologous transplantation.